Nasrien E Ibrahim1,2, James L Januzzi3,4,5. 1. Cardiology Division, Massachusetts General Hospital, 55 Fruit Street, GRB-800, Boston, MA, 02114, USA. neibrahim@mgh.harvard.edu. 2. Harvard Medical School, Boston, MA, USA. neibrahim@mgh.harvard.edu. 3. Cardiology Division, Massachusetts General Hospital, 55 Fruit Street, GRB-800, Boston, MA, 02114, USA. 4. Harvard Medical School, Boston, MA, USA. 5. Baim Institute for Clinical Research, Boston, MA, USA.
Abstract
PURPOSE OF REVIEW: Biomarker-guided management of patients with chronic heart failure with reduced ejection fraction (HFrEF) remains controversial. RECENT FINDINGS: Biomarkers have established roles for diagnosis and prognostication in HF. Pilot data suggested that use of natriuretic peptides might be helpful to guide HF care. The recent Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) randomized-controlled trial did not find therapy guided by NT-proBNP to be more effective than usual care in improving the primary endpoint of HF hospitalization or cardiovascular mortality amongst patients with chronic HFrEF. Patients in GUIDE-IT received similar care and had similar NT-proBNP lowering regardless of treatment allocation. Though biomarkers retain important standing for diagnosis and prognosis in HF, the GUIDE-IT trial results suggest carefully managed patients may not benefit from a biomarker-guided strategy. Future studies focusing this intervention on patients treated in a more real-world setting are needed.
RCT Entities:
PURPOSE OF REVIEW: Biomarker-guided management of patients with chronic heart failure with reduced ejection fraction (HFrEF) remains controversial. RECENT FINDINGS: Biomarkers have established roles for diagnosis and prognostication in HF. Pilot data suggested that use of natriuretic peptides might be helpful to guide HF care. The recent Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) randomized-controlled trial did not find therapy guided by NT-proBNP to be more effective than usual care in improving the primary endpoint of HF hospitalization or cardiovascular mortality amongst patients with chronic HFrEF. Patients in GUIDE-IT received similar care and had similar NT-proBNP lowering regardless of treatment allocation. Though biomarkers retain important standing for diagnosis and prognosis in HF, the GUIDE-IT trial results suggest carefully managed patients may not benefit from a biomarker-guided strategy. Future studies focusing this intervention on patients treated in a more real-world setting are needed.
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake Journal: J Am Coll Cardiol Date: 2017-04-28 Impact factor: 24.094
Authors: Michael R Zile; Brian L Claggett; Margaret F Prescott; John J V McMurray; Milton Packer; Jean L Rouleau; Karl Swedberg; Akshay S Desai; Jianjian Gong; Victor C Shi; Scott D Solomon Journal: J Am Coll Cardiol Date: 2016-12-06 Impact factor: 24.094
Authors: Friedrich M Fruhwald; Astrid Fahrleitner-Pammer; Rudolf Berger; Francisco Leyva; Nick Freemantle; Erland Erdmann; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi; Jean-Claude Daubert; John G F Cleland Journal: Eur Heart J Date: 2007-02-13 Impact factor: 29.983
Authors: Gregg C Fonarow; Nancy M Albert; Anne B Curtis; Wendy Gattis Stough; Mihai Gheorghiade; J Thomas Heywood; Mark L McBride; Patches Johnson Inge; Mandeep R Mehra; Christopher M O'Connor; Dwight Reynolds; Mary Norine Walsh; Clyde W Yancy Journal: Circulation Date: 2010-07-26 Impact factor: 29.690
Authors: Matthias Pfisterer; Peter Buser; Hans Rickli; Marc Gutmann; Paul Erne; Peter Rickenbacher; André Vuillomenet; Urs Jeker; Paul Dubach; Hansjürg Beer; Se-Il Yoon; Thomas Suter; Hans H Osterhues; Michael M Schieber; Patrick Hilti; Ruth Schindler; Hans-Peter Brunner-La Rocca Journal: JAMA Date: 2009-01-28 Impact factor: 56.272
Authors: Marvin A Konstam; James D Neaton; Kenneth Dickstein; Helmut Drexler; Michel Komajda; Felipe A Martinez; Gunter A J Riegger; William Malbecq; Ronald D Smith; Soneil Guptha; Philip A Poole-Wilson Journal: Lancet Date: 2009-11-16 Impact factor: 79.321
Authors: G Michael Felker; Tariq Ahmad; Kevin J Anstrom; Kirkwood F Adams; Lawton S Cooper; Justin A Ezekowitz; Mona Fiuzat; Nancy Houston-Miller; James L Januzzi; Eric S Leifer; Daniel B Mark; Patrice Desvigne-Nickens; Gayle Paynter; Ileana L Piña; David J Whellan; Christopher M O'Connor Journal: JACC Heart Fail Date: 2014-09-03 Impact factor: 12.035
Authors: Björn Eriksson; Per Wändell; Ulf Dahlström; Per Näsman; Lars H Lund; Magnus Edner Journal: Scand J Prim Health Care Date: 2019-11-14 Impact factor: 2.581
Authors: Paolo Morfino; Alberto Aimo; Vincenzo Castiglione; Giuseppe Vergaro; Michele Emdin; Aldo Clerico Journal: J Cardiovasc Dev Dis Date: 2022-08-10